Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$0.34
-1.7%
$0.42
$0.31
$2.70
$5.44M1.31219,783 shs231,661 shs
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
$2.00
+37.9%
$0.28
$0.11
$6.83
$64.99M0.1821.53 million shs129.17 million shs
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
$0.38
$0.38
$0.36
$4.80
$1.43MN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.16
-4.2%
$3.08
$1.75
$9.37
$5.11M1.38828,254 shs62,112 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
+4.67%+1.50%-17.15%-57.25%-86.15%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
-27.86%+701.55%+731.42%+417.86%+144,999,900.00%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00%0.00%0.00%0.00%0.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.30%-2.94%+4.10%+7.14%+1,525.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
2.8945 of 5 stars
3.52.00.00.03.01.71.3
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.2434 of 5 stars
0.03.00.00.02.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
3.00
Buy$8.502,406.64% Upside
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
0.00
N/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/A$1.44 per shareN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/A$2.11 per share0.95($2.16) per shareN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.37N/AN/A$3.01 per share1.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$15.42M-$1.49N/AN/AN/AN/A-177.27%-141.06%8/11/2025 (Estimated)
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
$1.35M-$0.36N/AN/AN/AN/A-25.89%N/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
-$4.37MN/A0.00N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)

Latest NBSE, KLTO, INDP, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A-$0.08N/A-$0.08N/AN/A
5/14/2025Q1 2025
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$0.41-$0.32+$0.09-$0.32N/AN/A
3/31/2025Q4 2024
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A-$0.07N/A-$0.07N/AN/A
3/13/2025Q4 2024
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$0.41-$0.38+$0.03-$0.38N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/AN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/A
3.42
3.42
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A
0.16
0.16
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49

Institutional Ownership

CompanyInstitutional Ownership
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
7.06%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
20.07%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
12.37%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
616.03 million9.96 millionNot Optionable
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A32.49 million26.54 millionN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
403.75 million3.46 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Indaptus Therapeutics stock logo

Indaptus Therapeutics NASDAQ:INDP

$0.34 -0.01 (-1.68%)
As of 04:00 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Klotho Neurosciences stock logo

Klotho Neurosciences NASDAQ:KLTO

$2.00 +0.55 (+37.93%)
As of 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

NeuBase Therapeutics stock logo

NeuBase Therapeutics NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.16 -0.14 (-4.24%)
As of 03:59 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.